This study is for people in South Korea who have cancer in or around the stomach (gastric cancer) or cancer where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Their cancer is locally advanced, unresectable, or metastatic. Locally advanced means the cancer has spread to tissue close by. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. In South Korea, VYLOY is approved for the treatment of gastric cancer or GEJ cancer. The people in this study will receive VYLOY as part of their usual treatment for their cancer. In standard clinical practice VYLOY is given to people slowly through a tube into a vein. The main aim of the study is to collect information in a real-world setting about the safety of VYLOY in people with gastric cancer or GEJ cancer in clinics in South Korea. This study will also help researchers learn how long people's gastric cancer or GEJ cancer stays stable. This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the sponsor (Astellas). The study will last about 1 year (54 weeks).
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Number of patients with an adverse event (AE)
Timeframe: Up to 54 Weeks after the first administration of VYLOY
Number of patients with an adverse drug reaction (ADR)
Timeframe: Up to 54 Weeks after the first administration of VYLOY
Number of patients with a serious AE (SAE)
Timeframe: Up to 54 Weeks after the first administration of VYLOY
Number of patients with a serious ADR (SADR)
Timeframe: Up to 54 Weeks after the first administration of VYLOY
Number of patients with an unexpected AE (UAE)
Timeframe: Up to 54 Weeks after the first administration of VYLOY
Number of patients with an unexpected ADR (UADR)
Timeframe: Up to 54 Weeks after the first administration of VYLOY
Number of patients who died during the study
Timeframe: Up to 54 Weeks after the first administration of VYLOY
Astellas Pharma Global Development, Inc.
Number patients with an AE leading to death
Timeframe: Up to 54 Weeks after the first administration of VYLOY
Number of patients with an important risk compared to number of patients evaluated
Timeframe: Up to 54 Weeks after the first administration of VYLOY